More vaccine news, this time from phase 3 trial of Johnson&Johnson:
According to the company, their vaccine based on an adenovirus was 66% effective at preventing moderate and severe #covid19, 28 days after vaccination.
prnewswire.com/news-releases/…
According to the company, their vaccine based on an adenovirus was 66% effective at preventing moderate and severe #covid19, 28 days after vaccination.
prnewswire.com/news-releases/…
Good news:
- Big study with 45,000 participants across multiple countries
-Vaccine was 85% effective in preventing severe disease overall
- all hospitalisations and deaths in placebo group
- efficacy against severe disease increased over time (no cases in vaccinees after day 49)
- Big study with 45,000 participants across multiple countries
-Vaccine was 85% effective in preventing severe disease overall
- all hospitalisations and deaths in placebo group
- efficacy against severe disease increased over time (no cases in vaccinees after day 49)
Most importantly:
This is a single-dose vaccine and only needs standard refrigeration.
That means of vaccines so far it is the easiest to distribute.
And plan is to produce one billion doses this year, so protection for one billion people hopefully.
This is a single-dose vaccine and only needs standard refrigeration.
That means of vaccines so far it is the easiest to distribute.
And plan is to produce one billion doses this year, so protection for one billion people hopefully.
The bad news:
Again a clear signal that vaccines are less efficacious against variant 501Y.V2
"The level of protection against moderate to severe COVID-19 infection was 72% in the United States, 66% in Latin America and 57% in South Africa, 28 days post-vaccination.”
Again a clear signal that vaccines are less efficacious against variant 501Y.V2
"The level of protection against moderate to severe COVID-19 infection was 72% in the United States, 66% in Latin America and 57% in South Africa, 28 days post-vaccination.”
As Tony Fauci just said at the presser:
“We can see that we are going to be challenged. .... It's really a wake up call for us to be nimble and to be able to adjust as this virus will continue for certain to evolve and to mutate as we get more pressure."
“We can see that we are going to be challenged. .... It's really a wake up call for us to be nimble and to be able to adjust as this virus will continue for certain to evolve and to mutate as we get more pressure."
But let me end on a positive here:
Protection against severe disease was the same in South Africa and other regions.
Overall this is great news for now for the world.
We have to vaccinate the world and at the same time prepare vaccine updates.
Protection against severe disease was the same in South Africa and other regions.
Overall this is great news for now for the world.
We have to vaccinate the world and at the same time prepare vaccine updates.
For those wondering who has bought doses of Johnson&Johnson vaccine so far:
EU was biggest buyer so far.
Here is a graph taken from
bloomberg.com/graphics/covid…
EU was biggest buyer so far.
Here is a graph taken from
bloomberg.com/graphics/covid…
On regulatory process:
Application expected "late next week to FDA and followed soon after by a number of regulatory filings including to the EU and the rest of the world”, says Mathai Mammen of Johnson and Johnson.
Application expected "late next week to FDA and followed soon after by a number of regulatory filings including to the EU and the rest of the world”, says Mathai Mammen of Johnson and Johnson.
Mathai explains his hypothesis on why vaccine is good against severe disease in SA too:
"reason we have such great activity against severe disease is that that's the form of disease where T cells are important, and B.1.135 has not been able to step around T cell activity"
"reason we have such great activity against severe disease is that that's the form of disease where T cells are important, and B.1.135 has not been able to step around T cell activity"
• • •
Missing some Tweet in this thread? You can try to
force a refresh
